Page last updated: 2024-09-03

imatinib mesylate and AIDS-Related Opportunistic Infections

imatinib mesylate has been researched along with AIDS-Related Opportunistic Infections in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aboulafia, D; Dezube, BJ; Honda, K; Koon, HB; Krown, SE; Lee, JY; Noy, A; Rapisuwon, S; Reid, EG; Rudek, MA; Wang, Z	1
Bubley, GJ; Chatis, P; Crosby, K; Dezube, BJ; Egorin, MJ; Koon, HB; Masiello, D; Miller, TE; Pantanowitz, L; Proper, J; Smith, B; Tahan, SR; Weeden, W	1

Trials

2 trial(s) available for imatinib mesylate and AIDS-Related Opportunistic Infections

Article	Year
Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-10, Volume: 32, Issue:5 Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antineoplastic Agents; Benzamides; Cytokines; Disease Progression; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sarcoma, Kaposi; Time Factors; Treatment Outcome; United States	2014
Imatinib-induced regression of AIDS-related Kaposi's sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-10, Volume: 23, Issue:5 Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antineoplastic Agents; Benzamides; Biopsy; Diarrhea; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Sarcoma, Kaposi; Signal Transduction; Skin Neoplasms; Vascular Endothelial Growth Factor A	2005

Article

Year

Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-10, Volume: 32, Issue:5

Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antineoplastic Agents; Benzamides; Cytokines; Disease Progression; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sarcoma, Kaposi; Time Factors; Treatment Outcome; United States

2014

Imatinib-induced regression of AIDS-related Kaposi's sarcoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-10, Volume: 23, Issue:5

Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antineoplastic Agents; Benzamides; Biopsy; Diarrhea; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Sarcoma, Kaposi; Signal Transduction; Skin Neoplasms; Vascular Endothelial Growth Factor A

2005